Statins in dermatology

International Journal of Dermatology

Volumn 49, Issue 11, 2010, Pages 1235-1243

  Jowkar, Farideh ^a   Namazi, Mohammad Reza ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CONTRACEPTIVE AGENT; EPIDERMAL GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; PROBUCOL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; SOMATOMEDIN; VITAMIN D;

ACNE; ACNE VULGARIS; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ALOPECIA; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; ARTHRITIS; ASTHMA; ATHEROSCLEROSIS; BASAL CELL CARCINOMA; BEDTIME DOSAGE; BULLOUS DERMATITIS; BULLOUS SKIN DISEASE; CHEILITIS; CHOLESTEROL EMBOLISM; CHRONIC ACTINIC DERMATITIS; CLINICAL TRIAL; CONTACT DERMATITIS; DERMATITIS; DERMATOMYOSITIS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DUPUYTREN CONTRACTURE; ECZEMA; EPIDERMIS HYPERPLASIA; ERYTHEMA; FIBROBLAST; GRAFT VERSUS HOST REACTION; HIRSUTISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; IMMUNOMODULATION; INFLAMMATION; KERATODERMA; LICHEN PLANUS; LICHENOID ERUPTION; LIPOMA; LUPUS LIKE SYNDROME; MELANOMA; METABOLIC DISORDER; METASTASIS; MYOPATHY; NEUROFIBROMATOSIS; NONHUMAN; PHOTOTOXICITY; PORPHYRIA CUTANEA TARDA; PRURITUS; PSORIASIS; PYODERMA GANGRENOSUM; REVIEW; RHABDOMYOLYSIS; ROSACEA; SEBORRHEA; SKIN CANCER; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TOXIC EPIDERMAL NECROLYSIS; UNSPECIFIED SIDE EFFECT; VITILIGO; WOUND HEALING; XANTHELASMA;

ANIMALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SKIN; SKIN DISEASES;

EID: 77958529553     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04579.x     Document Type: Review

References (84)

1. Hoogerwerf WA, Pasricha PJ. Phramacotherapy of gastric acidity, peptic ulcer and gastroesophageal reflux diseases. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's, 11th, New York: McGraw-Hill, 2006: 948.
2. Hou R, Goldberg AC. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrinol Metab Clin North Am 2009; 38: 79-97.
3. Sumi D, Hayashi T, Thakur NK, et al. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects - the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 2001; 155: 347-357.
4. Pasha MK, Muzeeb S, Basha SJ, et al. Analysis of five HMG-CoA reductase inhibitors - atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. Biomed Chromatogr 2006; 20: 282-293.
5. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA 2006; 295: 74-80.
6. Gniadecki R. Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. Biochem Biophys Res Commun 2004; 320: 165-169.
7. Koomen ER, Joosse A, Herings RMC, et al. Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin? Eur J Cancer 2007; 43: 2580-2589.
8. Feleszko W, Zagozdzon R, Golab J, Jakobisiak M. Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice. Eur J Cancer 1998; 34: 406-411.
9. Feleszko W, Mlynarczuk I, Olszewska D, et al. Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism. Int J Cancer 2002; 100: 111-118.
10. Collisson EA, Kleer C, Wu M, et al. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther 2003; 2: 941-948.
11. Depasquale I, Wheatley DN. Action of Lovastatin (Mevinolin) on an in vitro model of angiogenesis and its co-culture with malignant melanoma cell lines. Cancer Cell Int 2006; 6: 9.
12. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622.
13. Freeman SR, Drake AL, Heilig LF, et al. Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. J Natl Cancer Inst 2006; 98: 1538-1546.
14. Kuoppala J, Lamminpää A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 2008; 44: 2122-2132.
15. Glynn SA, O'Sullivan D, Eustace AJ, et al. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells. BMC Cancer 2008; 8: 9.
16. Dellavalle RP, Drake A, Graber M, et al. Statins and fibrates for preventing melanoma. Cochrane Database Syst Rev 2005; 4: CD003697.
17. Tang JY, So PL, Epstein EH Jr. Novel Hedgehog pathway targets against basal cell carcinoma. Toxicol Appl Pharmacol 2007; 224: 257-264. Epub 2006 Dec 21.
18. Namazi MR. Statins: novel additions to the dermatologic arsenal? Exp Dermatol 2004; 13: 337-339.
19. Rego AC, Araújo Filho I, Damasceno BP, et al. Simvastatin improves the healing of infected skin wounds of rats. Acta Cir Bras 2007; 22(Suppl. 1): 57-63.
20. Pruefer D, Makowski J, Schnell M, et al. Simvastatin inhibits inflammatory properties of Staphylococcus aureus á-toxin. Circulation 2002; 106: 2104-2110.
21. Maher BM, Dhonnchu TN, Burke JP, et al. Statins alter neutrophil migration by modulating cellular Rho activity - a potential mechanism for statins-mediated pleotropic effects? J Leukoc Biol 2009; 85: 186-193.
22. Guasti L, Marino F, Cosentino M, et al. Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1-year follow-up. Eur Heart J 2008; 29: 1118-1126.
23. Mira E, León B, Barber DF, et al. Statins induce regulatory T cell recruitment via a CCL1 dependent pathway. J Immunol 2008; 181: 3524-3534.
24. Goldstein MR, Mascitelli L, Pezzetta F. Statins, leptin and regulatory T cells. Nutr Metab Cardiovasc Dis 2008; 18: e27.
25. Leung BP, Sattar N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003; 170: 1524-1530.
26. Mckay A, Leung BP, McInnes IB, et al. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 2004; 172: 2903-2908.
27. Otuki MF, Pietrovski EF, Cabrini DA. Topical simvastatin: preclinical evidence for a treatment of skin inflammatory conditions. J Dermatol Sci 2006; 44: 45-47.
28. Davignon J, Jacob RF, Mason RP. The antioxidant effects of statins. Coron Artery Dis 2004; 15: 251-258.
29. Sorrentino S, Landmesser U. Nonlipid-lowering effects of statins. Curr Treat Options Cardiovasc Med 2005; 7: 459-466.
30. Kumar AP, Reynolds WF. Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun 2005; 331: 442-451.
31. Ajith TA, Riji T, Anu V. In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin. Clin Exp Pharmacol Physiol 2008; 35: 625-629.
32. Vincent TS, Wulfert E, Merler E. Inhibition of growth factor signaling pathways by lovastatin. Biochem Biophys Res Commun 1991; 180: 1284-1289.
33. Louneva N, Huaman G, Fertala J, Jiménez SA. Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum 2006; 54: 1298-1308.
34. Namazi H, Emami MJ. Simvastatin may be a useful therapy in Dupuytren contracture. Med Hypotheses 2006; 66: 683-684.
35. Park HJ, Kong D, Iruela-Arispe L, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002; 91: 143-150.
36. Bitto A, Minutoli L, Altavilla D, et al. Simvastatin enhances VEGF production and ameliorates impaired wound healing in experimental diabetes. Pharmacol Res 2008; 57: 159-169.
37. Katsumoto M, Shingu T, Kuwashima R, et al. Biphasic effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis. Circ J 2005; 69: 1547-1555.
38. Reiter M, Wirth S, Pourazim A, et al. Statin therapy has no significant effect on skin tissue cholesterol: results from a prospective randomized trial. Clin Chem 2005; 51: 252-254.
39. Babita K, Tiwary AK. Skin lipid synthesis inhibition: a possible means for enhancing percutaneous delivery of levodopa. Curr Drug Deliv 2004; 1: 397-403.
40. Ramsing D, Anger D, Malinowski J, et al. Effect of systemic treatment with cholesterol-lowering drugs on the skin barrier function in humans. Acta Derm Venereol 1995; 75: 198-201.
41. Brazzelli V, Distante F, Perani G, Berardesca E. Effects of systemic treatment with statins on skin barrier function and stratum corneum water-holding capacity. Dermatology 1996; 192: 214-216.
42. Dobs AS, Levine MA, Margolis S. Effects of pravastatin, a new HMG-CoA reductase inhibitor, on vitamin D synthesis in man. Metabolism 1991; 40: 524-528.
43. Shirinsky IV, Shirinsky VS. Efficacy of simvastatin in plaque psoriasis: a pilot study. J Am Acad Dermatol 2007; 57: 529-531.
44. Jacobi TC, Highetn A. A clinical dilemma while treating hypercholesterolaemia in psoriasis. Br J Dermatol 2003; 149: 1305-1306.
45. Aronson PJ, Friedman DB. Pharmacologic doses of lovastatin do not predictably affect the course of psoriasis. Arch Dermatol 1992; 128: 124.
46. Hori A, Kanda Y, Goyama S, et al. A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease. Transplantation 2005; 79: 372-374.
47. Noël M, Gagné C, Bergeron J, et al. Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo. Lipids Health Dis 2004; 3: 7.
48. Finch TM, Ryatt KS. Livedo reticularis caused by cholesterol embolization may improve with simvastatin. Br J Dermatol 2000; 143: 1319-1320.
49. Self TH, Akins D. Dramatic reduction in lipoma associated with statin therapy. J Am Acad Dermatol 2008; 58(2 Suppl.): S30-S31.
50. Fujita M, Shirari K. A comparative study of the therapeutic effect of probucol and pravastatin on xanthelasma. J Dermatol 1996; 23: 598-602.
51. Kolanczyk M, Kühnisch J, Kossler N, et al. Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin. BMC Med 2008; 6: 21.
52. Li W, Cui Y, Kushner SA, et al. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol 2005; 15: 1961-1967.
53. Wojtkowiak JW, Fouad F, LaLonde DT, et al. Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. J Pharmacol Exp Ther 2008; 326: 1-11.
54. Duque MI, Thevarajah S, Chan YH, et al. Uremic pruritus is associated with higher kt/V and serum calcium concentration. Clin Nephrol 2006; 66: 184-191.
55. Del Real G, Jiménez-Baranda S, Mira E, et al. Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 2004; 200: 541-547.
56. Gilbert C, Bergeron M, Méthot S, et al. Statins could be used to control replication of some viruses, including HIV-1. Viral Immunol 2005; 18: 474-489.
57. Namazi MR. Statins: novel weapons against granulomatous disorders and HIV infection? Acta Dermatovenerol Alp Panonica Adriat 2004; 13: 137.
58. Namazi MR. The potential utility of statin vaginal gels in the prevention of HIV transmission. J Drugs Dermatol 2005; 4: 16.Links.
59. Lanham MS, Lebovic DI, Domino SE. Contemporary medical therapy for polycystic ovary syndrome. Int J Gynaecol Obstet 2006; 95: 236-241.
60. Joshi R, Olver I, Keefe D, et al. A phase I study to assess the safety and activity of topical lovastatin (FP252S) for the prevention of chemotherapy-induced alopecia. Support Care Cancer 2007; 15: 1109-1112.
61. Toker S, Gulcan E, Cayc MK, et al. Topical atorvastatin in the treatment of diabetic wounds. Am J Med Sci 2009; 338: 201-204.
62. Proskch E. Antilipemic drug-induced skin manifestations. Hautartz 1995; 46: 76-80.
63. Kerasovec M, Elsner P, Burg G. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors. Dermatology 1993; 186: 248-252.
64. Schindl A, Trautinger F, Pernerstorfer-Schön H, et al. Porphyria cutanea tarda induced by the use of pravastatin. Arch Dermatol 1998; 134: 1305-1306.
65. Marguery MC, Chouini-Lalanne N, Drugeon C, et al. UV-B phototoxic effects induced by atorvastatin. Arch Dermatol 2006; 142: 1082-1084.
66. Srivastava M, Rencic A, Diglio G, et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol 2003; 139: 45-49.
67. Pua VS, Scolyer RA, Barnetson RS. Pravastatin-induced lichenoid drug eruption. Australas J Dermatol 2006; 47: 57-59.
68. Keough GC, Richardson TT, Grabski WJ. Pravastatin-induced lichenoid drug eruption. Cutis 1998; 61: 98-100.
69. Mehregan DR, Mehregan DA, Pakideh S. Cheilitis due to treatment with simvastatin. Cutis 1998; 62: 197-198.
70. Vasconcelos OM, Campbell WW. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 2004; 30: 803-807.
71. Noël B, Panizzon RG. Lupus-like syndrome associated with statin therapy. Dermatology 2004; 208: 276-277.
72. Oskay T, Kutluay L. Acute generalized exanthematous pustulosis induced by simvastatin. Clin Exp Dermatol 2003; 28: 558-559.
73. Pearse AD, Anstey AV. Chronic actinic dermatitis secondary to simvastatin. Photodermatol Photoimmunol Photomed 2002; 18: 313-314.
74. Stoebner PE, Michot C, Ligeron C, et al. Simvastatin-induced lichen planus pemphigoides. Ann Dermatol Venereol 2003; 130(2 Pt 1): 187-190.
75. Abadir R, Liebmann J. Radiation reaction recall following simvastatin therapy: a new observation. Clin Oncol (R Coll Radiol) 1995; 7: 325-326.
76. Field S, Bourke B, Hazelwood E, Bourke JF. Simvastatin - occupational contact dermatitis. Contact Dermatitis 2007; 57: 282-283.
77. Peramiquel L, Serra E, Dalmau J, et al. Occupational contact dermatitis from simvastatin. Contact Dermatitis 2005; 52: 286-287.
78. König C, Eickert A, Scharfetter-Kochanek K, et al. Linear IgA bullous dermatosis induced by atorvastatin. J Am Acad Dermatol 2001; 44: 689-692.
79. Pfeiffer CM, Kazenoff S, Rothberg HD. Toxic epidermal necrolysis from atorvastatin. JAMA 1998; 279: 1613-1614.
80. Horton SL, Hashimoto K, Toi Y, et al. Spiny keratoderma: a common under-reported dermatosis. J Dermatol 1998; 25: 353-361.
81. Quiec D, Mazière C, Auclair M, et al. Lovastatin enhances the photocytotoxicity of UVA radiation towards cultured N.C.T.C. 2544 human keratinocytes: prevention by cholesterol supplementation and by a cathepsin inhibitor. Biochem J 1995; 310(Pt 1): 305-309.
82. Segal AS. Alopecia associated with atorvastatin. Am J Med 2002; 113: 171.
83. Lee TH. By the way, doctor... My hair has been thinning out for the past decade or so, but since my doctor started me on Lipitor (atorvastatin) a few months ago for high cholesterol, I swear it's been falling out much faster. My doctor discounts the possibility, but I looked in the Physicians' desk reference (PDR) and alopecia is listed under "adverse reactions." What do you think? Harv Health Lett 2000; 25: 8.
84. Robb-Nicholson C. Recently, I heard on a TV show that anticholesterol drugs can cause hair loss. I've been taking Zocor for about 18-months now, and in the past 6-months I've noticed hair loss from the top and sides of my head. Is this common? Will my hair regrow once I stop taking the drug? Harv Womens Health Watch 1998; 5: 8.